Clinical Trials Sponsored by Merck Serono (GFI)

Total 199 results

University Hospital, Montpellier
Merck Serono (GFI)

Completed

Prospective Study of an Human Endometrial Receptivity Test (Win-Test)

Infertile

France
EMD Serono
Merck Serono International SA

Completed

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting
EMD Serono
Merck Serono International SA

Completed

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Multiple Sclerosis, Relapsing-remitting
EMD Serono
Merck Serono International SA

Completed

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Ulcerative Colitis

Sweden, Germany, Netherlands, Israel, Singapore, Switzerland, United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono Norway

Completed

A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth

Infertility

Norway
Isala
Merck Serono International SA

Unknown

Predicting Ovarian Response in Artificial Insemination With Low Stimulation

Subfertility

Netherlands
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd.

Terminated

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Infertility

China
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK (ECOS UK)

Growth Disorders

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Terminated

Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle (ENDOMEDE)

Infertility

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Hypochondroplasia

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (CHOLINE)

Multiple Sclerosis

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin) (SEPAGE)

Infant, Small for Gestational Age

France
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Relapsing Multiple Sclerosis

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement

Knee Osteoarthritis

Denmark, Finland, Sweden, United Kingdom, Bulgaria, South Africa
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany

Completed

To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen

Infertility | Ovulation Induction
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device (READER)

Relapsing Multiple Sclerosis

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Terminated

EXpression PRofile Endometrium Samples Study (EXPRESS)

In Vitro Fertilization

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients (SEPTIME)

Multiple Sclerosis, Relapsing, Remitting
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

Saizen in Intra-uterine Growth Retardation

Children Born With Serious Intra-uterine Growth Retardation
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN)

Multiple Sclerosis

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy (ECOS ITA)

Growth Disorders

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France (ECOS FRA)

Growth Disorders

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany

Completed

Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone) (LODOTRA)

Arthritis, Rheumatoid

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Assessment of Patient Use of a New Device: RebiSmart

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Serono S.A.S, France

Completed

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (ATTAC-PCO)

Polycystic Ovarian Syndrome

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease (REAL)

Alzheimer's Disease

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration

Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study

Turner Syndrome | Idiopathic Growth Hormone Deficiency

Spain, France, Canada, United Kingdom, Czech Republic, Argentina, Germany, Italy, Sweden
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Terminated

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA) (SAIZEN in SGA)

Infant, Small for Gestational Age

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. (SMART)

Multiple Sclerosis, Relapsing-Remitting

Netherlands
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

Trial of MSC1936369B in Subjects With Solid Tumors

Cancer | Solid Tumors

France, Belgium, Australia, Netherlands
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice (RESECT)

Metastatic Colorectal Cancer

United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Terminated

Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle (Luveris in ART)

Reproductive Techniques, Assisted

Italy
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaborators

Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PERSIST)

Assisted Reproductive Techniques | Reproductive Technology, Assisted

Italy, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation (ARTIST)

Polycystic Ovary Syndrome

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment (ECOS CHN)

Growth Disorders

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Terminated

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Hepatocellular Carcinoma | Advanced Solid Tumors

Japan
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients (CREATIVE)

Hypertension

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

Dwarfism, Pituitary
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Terminated

Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants (SPET)

Non-obstructive Coronary Artery Disease

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Terminated

Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants (Biso-CHF)

Heart Failure

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension

Hypertension

China
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Terminated

Colposeptine for the Treatment of Bacterial Vaginosis

Vaginosis, Bacterial

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease (RESPOND)

Non-Obstructive Coronary Artery Disease

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia (ECOS AUS)

Growth Disorders

Australia
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., China

Completed

Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina (SIGMART)

Coronary Disease | Stable Angina

China
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Polycystic Ovarian Syndrome | Anovulation | Oligo-ovulation | Hypothalamic-pituitary Dysfunction

Japan
Merck KGaA, Darmstadt, Germany
Merck Serono Co., Ltd., Japan

Completed

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Non-small Cell Lung Cancer

Germany

3

Subscribe